Skip to main content
. 2017 May 23;55(6):1747–1754. doi: 10.1128/JCM.00274-17

TABLE 1.

MIC values for tedizolid and comparative antimicrobials against isolates of nontuberculous mycobacteria

Species (no. of isolates tested) Intermediate breakpoint (μg/ml) Antimicrobial agent MIC (μg/ml)
Range 50% 90%
Rapidly growing species
    M. abscessus subsp. abscessus (81) a Tedizolid 0.12–>32 4 8
16 Linezolid 0.25–128 16 32
32 Amikacin 2–>1024 16 32
32–64 Cefoxitin 16–64 32 64
2 Ciprofloxacin 0.5–>4 >4 >4
4 Clarithromycinb 0.5–>16 >16 >16
2–4 Doxycycline 8–>16 >16 >16
8–16 Imipenem 4–>64 16 32
2–4 Minocycline 2–>8 >8 >8
2 Moxifloxacin 2–>8 8 >8
Tigecyclinec 0.03–0.5 0.25 0.5
TMP-SMXd ≤0.25/4.75–8/152 4/76 8/152
    M. abscessus subsp. massiliense (12) Tedizolid 0.12–>32 2 4
16 Linezolid 0.5–32 8 32
32 Amikacin 4–>1024 16 64
32–64 Cefoxitin 32–64 32 64
2 Ciprofloxacin 1–>4 4 4
4 Clarithromycinb 0.12–>128 0.5 2
2–4 Doxycycline 0.25–>16 >16 >16
8–16 Imipenem 8–32 8 16
2–4 Minocycline ≤1–>8 >8 >8
2 Moxifloxacin 2–>8 8 >8
Tigecyclinec 0.06–0.5 0.25 0.5
TMP-SMXd 4/76–>8/152 4/76 >8/152
    M. abscessus subsp. massiliense/M. abscessus subsp. abscessus hybride (6) Tedizolid 0.25–>32 0.5
16 Linezolid 2–>128 16
32 Amikacin 16–64 16
32–64 Cefoxitin 16–64 32
2 Ciprofloxacin 4–>4 4
4 Clarithromycina 0.12–16 1
2–4 Doxycycline >16 >16
8–16 Imipenem 8–16 16
2–4 Minocycline >8 >8
2 Moxifloxacin 4–>8 4
Tigecyclinec 0.12–0.25 0.12
TMP-SMXd 2/38–8/152 4/76
    M. chelonae (22) Tedizolid 0.25–4 1 2
16 Linezolid 2–16 8 16
32 Amikacin 8–32 16 32
32–64 Cefoxitin 128–>128 >128 >128
2 Ciprofloxacin 0.5–>4 4 >4
4 Clarithromycina ≤0.06–>128 1 2
2–4 Doxycycline 2–>16 >16 >16
8–16 Imipenem 8–64 16 32
2–4 Minocycline ≤1–>8 >8 >8
2 Moxifloxacin 1–>8 4 8
Tigecyclinec 0.06–0.5 0.25 0.5
Tobramycin ≤1–2 2 2
TMP-SMXd 1/19–>8/152 4/76 >8/152
    M. mucogenicum group (9) Tedizolid 0.06–4 1
16 Linezolid 0.5–8 1
32 Amikacin ≤0.5–4 1
32–64 Cefoxitin 4–16 16
2 Ciprofloxacin 0.25–>4 0.5
4 Clarithromycina 0.25–2 1
2–4 Doxycycline 0.25–>16 16
8–16 Imipenem ≤2 ≤2
2–4 Minocycline 1–>8 >8
2 Moxifloxacin ≤0.12–2 0.5
Tigecyclinec 0.03–0.25 0.25
TMP-SMXd ≤0.25/4.75–0.5/9.5 ≤0.25/4.75
    M. immunogenum (9) Tedizolid 0.5–4 1
16 Linezolid 0.12–16 8
32 Amikacin 8–16 8
32–64 Cefoxitin 8–>128 >128
2 Ciprofloxacin 2–>4 4
4 Clarithromycina 0.5–2 2
2–4 Doxycycline >16 >16
8–16 Imipenem 16–64 16
2–4 Minocycline >8 >8
2 Moxifloxacin 1–>8 8
Tigecyclinec 0.06–0.5 0.25
Tobramycin 4–16 16
TMP-SMXd 4/76–>8/152 8/152
    M. fortuitum (20) Tedizolid 0.25–2 1 2
16 Linezolid 1–8 2 4
32 Amikacin ≤1 ≤1 ≤1
32–64 Cefoxitin 8–64 32 64
2 Ciprofloxacin ≤0.12–0.25 ≤0.12 ≤0.12
4 Clarithromycina ≤0.06–128 32 64
2–4 Doxycycline ≤0.12–>16 0.5 >16
8–16 Imipenem ≤2–4 4 4
2–4 Minocycline ≤1–>8 ≤1 >8
2 Moxifloxacin ≤0.25 ≤0.25 ≤0.25
Tigecyclinec 0.03–0.5 0.12 0.25
TMP-SMXd ≤0.25/4.75–2/38 0.5/9.5 1/19
Slowly growing species
    M. avium complex (100) Tedizolid 1–>32 8 >32
16 Linezolid 2–128 32 64
Amikacinf 2–>1024 32 128
16 Clarithromycin 0.25–>128 2 8
2 Moxifloxacin 0.25–>8 4 8
    M. arupense (9) Tedizolid 1–4 4
16 Linezolid 8–32 16
32 Amikacin 32–>1024 64
2 Ciprofloxacin 16–>16 >16
16 Clarithromycin 0.25–1 0.5
4 Doxycycline 4–>16 1
4 Ethambutol ≤0.5–8 >16
2 Moxifloxacin >8 >8
2 Rifabutin ≤0.25–1 ≤0.25
2 Rifampin 2–>8 8
TMP-SMXd 0.5/9/5–4/76 2/38
    M. kansasii (7) Tedizolid 0.25–1 0.5
16 Linezolid 0.5–2 2
32 Amikacin 2–64 8
2 Ciprofloxacin 1–>16 2
16 Clarithromycin ≤0.06–1 0.25
4 Doxycycline 2–>16 16
4 Ethambutol 2–8 4
2 Moxifloxacin ≤0.12–0.5 0.25
2 Rifabutin ≤0.25–0.5 ≤0.25
2 Rifampin ≤0.12–4 0.25
TMP-SMXd ≤0.12/2.38–0.5/9.5 ≤0.12/2.38
    M. simiae (8) Tedizolid 1–>32 8
16 Linezolid 8–128 64
32 Amikacin 32–128 32
2 Ciprofloxacin 16–>16 16
16 Clarithromycin 8–>64 8
4 Doxycycline >16 >16
4 Ethambutol 16–>16 >16
2 Moxifloxacin 4–>8 4
2 Rifabutin 8–>8 >8
2 Rifampin >8 >8
TMP-SMXd 1/19–4/76 2/38
    M. marinum (7) Tedizolid 0.25–1 1
16 Linezolid 1–4 1
32 Amikacin ≤1–4 ≤1
2 Ciprofloxacin 4–16 8
16 Clarithromycin 0.25–1 0.5
4 Doxycycline 2–8 2
4 Ethambutol ≤0.5–4 4
2 Moxifloxacin 0.5–8 1
2 Rifabutin ≤0.25 ≤0.25
2 Rifampin ≤0.12–1 0.5
TMP-SMXd 0.5/9.5–2/38 1/19
a

—, not determined.

b

Clarithromycin MIC is the result of extended incubation (up to 14 days) to detect macrolide resistance induced by the erm gene.

c

There is currently no CLSI-recommended breakpoint for tigecycline.

d

TMP-SMX, trimethoprim sulfamethoxazole. There is no intermediate breakpoint for TMP-SMX; resistance is ≥4/76 μg/ml.

e

There is currently no CLSI-recommended amikacin breakpoint for M. avium complex. A proposed resistance breakpoint associated with a 16S rRNA gene mutation (1408A→C) is >64 μg/ml (11).

f

M. abscessus subsp. massiliense by erm/M. abscessus subsp. abscessus by rpoB gene (a “hybrid” subspecies or may represent a new species).